跳至主要内容
临床试验/TCTR20220209003
TCTR20220209003已完成4 期

A comparative trial of metabolic parameters and cardiovascular risk in chronic hepatitis B patients who were treated with Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide.

Faculty of medicine, Siriraj Hospital0 个研究点目标入组 90 人开始时间: 2022年2月9日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
入组人数
90

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
40 Years 至 75 Years(—)
性别
All

入选标准

  • 1.Chronic HBV infection patient, age 40-75 yr.
  • 2.Currently on TDF at least 1 yr and undetectable HBV viral load
  • 3.Estimated GFR > 50 ml/min/1.73m
  • 4.LDL cholesterol < 130 ml/dL more than 6 months or < 100 ml/dL in DM

排除标准

  • 1.Co-infection with HCV or HIV
  • 2.Patients who currently had other cancer or HCC
  • 3.Patients who had cirrhosis or clinical liver decompensatiom
  • 4.Previous organ transplantation
  • 5.Previous diagnosed with stroke or coronary artery disease
  • 6.Currently on immunosuppresive drugs
  • 7.Patients whom plan to pregnant or current pregnant
  • 8.Initial carotid doppler ultrasonography show carotid stenosis > 70%
  • 9.Patients who had history of alcohol drinking > 2 standard drinks in male or > 1 standard drink in female

研究者

相似试验